A 21L/BA.2-21K/BA.1 “MixOmicron” SARS-CoV-2 hybrid undetected by qPCR that screen for variant in routine diagnosis - Colson, Philippe; Delerce, Jeremy; Marion-Paris, Elise; Lagier, Jean-Christophe; Levasseur, Anthony; Fournier, Pierre-Edouard; La Scola, Bernard; Raoult, Didier (medRxiv, 2022)
Among the multiple SARS-CoV-2 variants identified since summer 2020, several have co-circulated, creating opportunities for coinfections and potentially genetic recombinations that are common in coronaviruses. Viral recombinants are indeed beginning to be reported more frequently. Here, we describe a new SARS-CoV-2 recombinant genome that is mostly that of a Omicron 21L/BA.2 variant but with a 3’ tip originating from a Omicron 21K/BA.1 variant. Two such genomes were obtained in our institute from adults sampled in February 2022 in university hospitals of Marseille, southern France, by next-generation sequencing carried out with the Illumina or Nanopore technologies. The recombination site was located between nucleotides 26,858-27,382. In the two genomic assemblies, mean sequencing depth at mutation-harboring positions was 271 and 1,362 reads and mean prevalence of the majoritary nucleotide was 99.3 extpm2.2% and 98.8 extpm1.6%, respectively. Phylogeny generated trees with slightly different topologies according to whether genomes were depleted or not of the 3’ tip. This 3’ terminal end brought in the Omicron 21L/BA.2 genome a short transposable element of 41 nucleotides named S2m that is present in most SARS-CoV-2 except a few variants among which the Omicron 21L/BA.2 variant and may be involved in virulence. Importantly, this recombinant is not detected by currently used qPCR that screen for variants in routine diagnosis. The present observation emphasizes the need to survey closely the genetic pathways of SARS-CoV-2 variability by whole genome sequencing, and it could contribute to gain a better understanding of factors that lead to observed differences between epidemic potentials of the different variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future program managed by the National Agency for Research (ANR) (Mediterranee-Infection 10-IAHU-03), by the Region Provence Alpes Cote d Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d Innovation Mutualisees Mediterranee Infection) (FEDER PA 0000320 PRIMMI), and by the French Ministry of Higher Education, Research and Innovation (Ministere de l’Enseignement superieur, de la Recherche et de l Innovation) and the French Ministry of Solidarity and Health (Ministere des Solidarites et de la Sante).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the ethics committee of the University Hospital Institute Mediterranee Infection (No. 2022-008). Access to the patients biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hopitaux de Marseille (AP-HM) and was recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequences generated and analyzed in the present study are available from the NCBI GenBank nucleotide sequence database (https://www.ncbi.nlm.nih.gov/ genbank/) (Accession no. OM993515 and OM993473), from the IHU Mediterranee Infection website (https://www.mediterranee-infection.com/sars-cov-2-recombinant/) (IHUCOVID-063942 and IHUCOVID-068136), and from the GISAID database (https://www.gisaid.org/) (EPI_ISL_10843457, EPI_ISL_10047082). https://www.ncbi.nlm.nih.gov/genbank/ https://www.mediterranee-infection.com/sars-cov-2-recombinant/ https://www.gisaid.org/